CTOs on the Move

Glympse Bio

www.glympsebio.com

 
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.glympsebio.com
  • LabCentral, 700 Main Street
    Cambridge, MA USA 02139
  • Phone: 617.863.3650

Executives

Name Title Contact Details

Funding

Glympse Bio raised $22M on 10/09/2018
Glympse Bio raised $46.7M on 07/15/2020

Similar Companies

Piedmont Medical Laboratory

Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.

Abengoa Bioenergy Corporation

Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Avalo Therapeutics Inc

Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.

Cerecin

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat diseases of the brain. Cerecin`s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of medium-chain triglycerides. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world`s leading manufacturers of fatty acids and lipids. Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.